<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799979</url>
  </required_header>
  <id_info>
    <org_study_id>14-AOI-08</org_study_id>
    <nct_id>NCT02799979</nct_id>
  </id_info>
  <brief_title>3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension</brief_title>
  <acronym>HTP3S</acronym>
  <official_title>3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertension is a rare and severe disease, affecting a young population. Survival&#xD;
      is very poor and has been closely related to right ventricular dysfunction. Current&#xD;
      prognostic equations rely mostly on right heart catheterization data. The identification of&#xD;
      simple echocardiographic prognostic factor is urgently needed. It could help identifying with&#xD;
      a non invasive method, high risk patients who could benefit from an intensive specific&#xD;
      therapy. 3D right ventricular imaging is a new echocardiographic tool which provides RV&#xD;
      volumic analysis, RV ejection fraction, overcoming the classical limits of 2D ultrasound.&#xD;
&#xD;
      The aim of this study is to validate a new software for 3D analysis of the right ventricle&#xD;
      and assess its prognostic role in pulmonary hypertension.&#xD;
&#xD;
      To do so, the investigators will realize a prospective monocentric longitudinal cohort study,&#xD;
      including 100 pulmonary hypertension patients. Echocardiographic data will be collected at&#xD;
      baseline and after 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of death from any cause</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Description of the number of death during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalisation</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>Description of the number of hospitalisation for worsening of pulmonary arterial hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3D right ventricular imaging echocardiographic</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Analyse the data of 3D right ventricular (RV), ejection fraction, RV telediastolic and telesystolic volume, 3D RV area strain (%)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>Echocardiographic data : 3D right ventricular imaging on 100 pulmonary hypertension patients at Baseline and after six months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Echocardiographic data : 3D right ventricular Imaging on 50 patients without pulmonary hypertension only at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D right ventricular imaging echocardiographic</intervention_name>
    <description>Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with pulmonary hypertension diagnosed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18 years old&#xD;
&#xD;
          -  Pulmonary hypertension diagnosed by right heart catheterization&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
          -  Affiliation to the French national health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Associated significant left heart disease&#xD;
&#xD;
          -  Sub-optimal acoustic windows&#xD;
&#xD;
          -  Patient unable to attend follow-up visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PAMELA MOCERI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU NICE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PAMELA MOCERI, MD</last_name>
    <phone>4 92 03 77 34</phone>
    <phone_ext>+33</phone_ext>
    <email>moceri.p@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Pasteur - Chu Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PAMELA MOCERI, MD</last_name>
      <phone>4 92 03 77 34</phone>
      <phone_ext>+33</phone_ext>
      <email>moceri.p@chu-nice.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

